RxDoctor Payments Data

Gilberta Theonnes

Psychiatric/Mental Health · Elko, NVNPI 1801171384

Payments from drug & device makers

$433in general payments, 2019–2025

Across 25 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$138
  • Takeda Pharmaceuticals U.S.A., Inc.$84
  • Indivior Inc.$77
  • Teva Pharmaceuticals USA, Inc.$69
  • Alkermes, Inc.$36
  • Harmony Biosciences LLC$15
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$433100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$433 in reported general payments places this provider in the 35th percentile of 362 psychiatric/mental health providers in Nevada.

See all psychiatric/mental health providers in Nevada

Medicare billing

Part B allowed, 2024
$18,095
Medicare patients
65
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate35$97,833
Risperidone ErRisperidone Microspheres12$11,867
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl38$11,210
TrintellixVortioxetine Hydrobromide13$8,772
Aripiprazole22$7,419
Lurasidone Hcl21$5,891
Clozapine12$3,476
Paliperidone ErPaliperidone15$3,242
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$1,538
Alprazolam66$1,019
Buspirone Hcl40$879
Quetiapine Fumarate46$731
Clonazepam77$620
Divalproex Sodium21$606
Lorazepam54$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$84$8,77213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 362 psychiatric/mental health providers in Nevada.

Other psychiatric/mental health in Elko

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →